Study With Oral Isovue in Abdominopelvic CT
Launched by BRACCO DIAGNOSTICS, INC · Jun 26, 2020
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Patients will be included in the study if:
- • Demographic and safety data are available for analysis
- • Complete set of CT images performed after oral administration of Isovue-300 are available for assessment
- • Isovue-300 was orally administered during an interval time of 60-20 minutes before the CT scanning.
- Patients will be excluded from the study if:
- • Oral contrast agent received within 1 week prior to the CT scan
- • Undergone any abdominopelvic surgery procedure that resulted in alteration of the bowel transit time prior to the CT exam
- • CT exam with oral administration of Isovue was performed because of a known or suspected condition of bowel obstruction
- • Patient did not actively drink the contrast solution.
About Bracco Diagnostics, Inc
Bracco Diagnostics Inc. is a leading global provider of imaging agents and solutions, dedicated to enhancing patient care through innovative diagnostic technologies. With a strong focus on research and development, Bracco specializes in creating high-quality contrast agents for medical imaging modalities, including MRI, CT, and ultrasound. The company is committed to advancing healthcare by improving the accuracy and efficacy of diagnostic procedures, ensuring safety, and supporting healthcare professionals in making informed clinical decisions. Through partnerships and clinical trials, Bracco Diagnostics actively contributes to the development of cutting-edge imaging solutions, ultimately aiming to improve patient outcomes and streamline diagnostic processes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Akron, Ohio, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials